肿瘤化疗止吐剂格拉司琼透皮贴剂的研究进展  

Progress in research of granisetron transdermal patch for chemotherapy-induced nausea and vomiting

作　　者：张亮[1] 徐丽华[1] 叶金翠[1] 

机构地区：[1]浙江省医学科学院药物研究所,杭州310013

出　　处：《中国新药杂志》2012年第13期1443-1447,共5页Chinese Journal of New Drugs

基　　金：国家自然科学基金(30901871);浙江省科技计划项目(2010F20019);浙江省医学重点学科群建设(XKQ-010-001)

摘　　要：恶心与呕吐是癌症患者接受化疗后最常见的毒副作用,严重影响患者的生存质量和对化疗的依从性。5-羟色胺3(5-HT3)受体拮抗剂是目前最有效的止吐剂,临床以静脉注射或者口服的方式给药。格拉司琼透皮贴剂于2008年被美国FDA批准用于控制化疗患者恶心与呕吐,是首个上市的5-HT3受体拮抗剂透皮贴剂。本文根据国内外文献,对格拉司琼透皮贴剂的药学特点、药效学、药代动力学、临床研究近况及使用中存在的一些不足等进行综述。Nausea and vomiting are the most common side effects in patients receiving chemotherapy, which seriously affect the quality of life of patients and compliance with chemotherapy. The antagonists of 5- hydroxytryptamine-3 （5-HT3） receptors are most effective in treating chemotheapy-induced nausea and vomiting. Oral or intravenous administration has been used in clinical practice. Transdermal granisetron was approved in 2008 by FDA for the treatment of chemotherapy-induced nausea and vomiting. It is the first licensed transdermal 5-HT3 receptor antagonists in the world. In this paper, we reviewed the pharmaceutical features, pharmacodynamics, pharmacokinetics and clinical research of granisetron transdermal patch. The shortness of the patch use is also pointed out.

关 键 词：5-羟色胺3 格拉司琼透皮贴剂 化疗引起的恶心与呕吐 临床研究 

分 类 号：R975.4[医药卫生—药品]